FDA grants orphan drug designation to BIV201 for treatment of Acsites

Release Date: 11-Oct-2016

BioVie Inc., a company dedicated to discovering and developing therapeutic drugs, declares that it’s new drug candidate BIV201 has received orphan drug designation for the treatment of acsites due to chronic liver cirrhosis.
Currently, BioVie is looking forward to complete an investigational new drug (IND) application for BIV201 having potent vasoconstrictor as an active ingredient, which qualifies the drug for effective treatment of various life threatening diseases including type 1 hepatorenal syndrome (HRS), esophageal variceal bleeds, and sepsis.



For Orphan Drug Clinical Insight Reports Contact: neeraj@kuickresearch.com

Need custom market research solution? We can help you with that too.